Alumis Past Earnings Performance
Past criteria checks 0/6
Alumis's earnings have been declining at an average annual rate of -37.8%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually.
Key information
-37.8%
Earnings growth rate
-7.0%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | n/a |
Return on equity | -154.0% |
Net Margin | n/a |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Alumis makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 0 | -169 | 22 | 147 |
31 Dec 23 | 0 | -155 | 20 | 138 |
Quality Earnings: ALMS is currently unprofitable.
Growing Profit Margin: ALMS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if ALMS's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare ALMS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALMS is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (13%).
Return on Equity
High ROE: ALMS has a negative Return on Equity (-153.96%), as it is currently unprofitable.